Lineage Cell Therapeutics to Host Therapeutic Area Experts at Solebury Trout Investor Event on November 15, 2019
October 28 2019 - 8:00AM
Business Wire
Lineage Cell Therapeutics, Inc.
(NYSE American and TASE: LCTX), a clinical-stage biotechnology
company developing novel cell therapies for unmet medical needs,
announced today that it will participate in Solebury Trout’s KOL
Event for analysts and investors on November 15, 2019 at 11am ET in
New York City at the offices of White & Case, LLP. Lineage will
begin with a corporate overview from Brian M. Culley, Chief
Executive Officer and Edward D. Wirth, III, MD, PhD, Chief Medical
Officer, which will be followed by presentations from Lineage
therapeutic area experts Allen C. Ho, MD, FACS, Wills Eye Hospital
Attending Surgeon and Director of Retina Research and John Steeves,
BSc, PhD, Emeritus Principal Investigator, ICORD and Professor,
Department of Neuroscience at the University of British
Columbia.
Interested parties can access a live webcast of the Lineage
presentations on the Events and Presentations section of Lineage’s
website and an archived presentation will be available for 30
days.
Lineage Therapeutic Area
Experts
OpRegen® Clinical Program
Allen C. Ho, M.D. FACS, Wills Eye Hospital Attending
Surgeon and Director of Retina Research, Professor of
Ophthalmology, Thomas Jefferson University
Dr. Ho maintains special interests in macular diseases, diabetic
retinopathy, surgical retinal diseases and clinical trials
investigating new treatments for vitreoretinal diseases including
gene and cell therapies and new surgical drug delivery devices and
techniques. His experience includes collaborative translational and
clinical trial clinical research with expertise in study design,
methodological testing, data analyses, surgical instrumentation and
procedure development, execution and communication of these studies
and their study results. He is the current President of The Retina
Society and serves on its Executive Committee.
He has been Study Chair, Steering Committee Member or Principal
Investigator of over 50 clinical trials. Dr. Ho has served on the
US FDA Ophthalmic Device Panel, American Academy of Ophthalmology
(AAO) Ophthalmic Retina Technology Assessment Committee, AAO Retina
Measures Group, AAO IRIS Registry Committee and is past Chair of
the AAO Retina Subspecialty Days and Vail Vitrectomy meetings.
Through the Wills Eye Hospital Retina Fellowship he has mentored
over 60 retina fellows and international research trainees. Dr. Ho
has authored over 200 peer reviewed publications and several
textbooks and is Editor-in-Chief of Current Opinion in
Ophthalmology and Chief Medical Editor of Retina Today.
OPC1 Clinical
Program
John Steeves, B.Sc.,
Ph.D., Emeritus Principal Investigator, ICORD, Professor,
Department of Neuroscience, University of British Columbia
Dr. Steeves is currently a Professor in the Department of
Neuroscience at the University of British Columbia and a Principal
Investigator and Founding Director of ICORD (International
Collaboration On Repair Discoveries), an interdisciplinary research
centre focused on spinal cord injury. He also serves as the Chair
of SCOPE (Spinal Cord Outcomes Partnership Endeavor), which works
on translating discoveries to clinical trials. He obtained his
B.Sc. and Ph.D. at the University of Manitoba and completed his
Post-Doctoral Fellowship at the University of Alberta.
After a long career in basic science research, Dr. Steeves has
turned his attention to translational research, making application
of research to patients a higher priority. His current research
focuses on arm and hand rehabilitation after spinal cord injuries.
His goal is to improve rehabilitation strategies by using assistive
robots and virtual-reality training. With a number of colleagues
from across the globe, Dr. Steeves also works on developing better
criteria for enrolling participants in SCI clinical trials, and on
improving outcome measures of the electrical properties of the body
and the nervous system. Better measurements of the outcomes of
clinical trials can establish how well they help people with SCI,
and therefore promote better recovery.
Dr. Steeves also collaborates with EMSCI (European Multicenter
Study about Spinal Cord Injury) to analyze the database on SCI
patients and their injuries to determine better clinical trial
protocols.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology
company developing novel cell therapies for unmet medical needs.
Lineage’s programs are based on its proprietary cell-based therapy
platform and associated development and manufacturing capabilities.
With this platform Lineage develops and manufactures specialized,
terminally-differentiated human cells from its pluripotent and
progenitor cell starting materials. These differentiated cells are
developed either to replace or support cells that are dysfunctional
or absent due to degenerative disease or traumatic injury or
administered as a means of helping the body mount an effective
immune response to cancer. Lineage’s clinical assets include (i)
OpRegen®, a retinal pigment epithelium transplant therapy in Phase
I/IIa development for the treatment of dry age-related macular
degeneration, a leading cause of blindness in the developed world;
(ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase
I/IIa development for the treatment of acute spinal cord injuries;
and (iii) VAC2, an allogeneic cancer immunotherapy of
antigen-presenting dendritic cells currently in Phase I development
for the treatment of non-small cell lung cancer. Lineage is also
evaluating potential partnership opportunities for Renevia®, a
facial aesthetics product that was recently granted a Conformité
Européenne (CE) Mark. For more information, please visit
www.lineagecell.com or follow the Company on Twitter
@LineageCell.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191028005251/en/
Lineage Cell Therapeutics, Inc. IR Ioana C. Hone
(ir@lineagecell.com) (510) 871-4188
Solebury Trout IR Gitanjali Jain Ogawa
(Gogawa@troutgroup.com) (646) 378-2949
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Apr 2023 to Apr 2024